Across TCGA pan-cancer cohorts, ZNF829 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF829 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF829 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF829 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, BRCA, and SKCM are the cancer types where ZNF829 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	15	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	9	view →
UCEC	DFS	Median	All	0.928	0.621	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF829 tumor-vs-normal RNA expression · all ZNF829 data types